As ALK prepares to further extend their SLIT-tablet portfolio, tablet formulation is seen as key in delivering consistent positive clinical trial results
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
